Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases.
Current pharmacotherapeutic options for treating obesity and related metabolic disorders remain limited and ineffective. Emerging evidence shows that modulators of angiogenesis affect the expansion and metabolism of fat mass by regulating the growth and remodelling of the adipose tissue vasculature. Pharmacological manipulation of adipose tissue neovascularization by angiogenic stimulators and inhibitors might therefore offer a novel therapeutic option for the treatment of obesity and related metabolic disorders. This Perspective discusses recent progress in understanding the molecular mechanisms that control adipose tissue angiogenesis and in defining potential new vascular targets and approaches for the treatment of this group of diseases.
Cao
Yihai
Y
Yihai Cao is at the Department of Microbiology, Tumour and Cell Biology, Karolinska Institute, 171 77 Stockholm. yihai.cao@ki.se
D000273:Adipose Tissue / Q000098:blood supply / Q000187:drug effects*; D043925:Angiogenesis Inducing Agents / Q000494:pharmacology / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D006801:Humans; D008659:Metabolic Diseases / Q000188:drug therapy / Q000503:physiopathology; D018919:Neovascularization, Physiologic / Q000187:drug effects; D009765:Obesity / Q000188:drug therapy* / Q000503:physiopathology
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors; D019440:Anti-Obesity Agents